Asceneuron S.A.: Clinical Trials

5 trials sponsored by Asceneuron S.A., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Terminated 1
Phase 21Terminated 1

Follow Asceneuron S.A.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of ASN51 in Adults With Early Alzheimer's Disease
ASN51, Placebo - Alzheimer Disease
Phase 2TerminatedAsceneuron S.A.1232024-10-162025-06-29
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Fluvoxamine, Itraconazole, Paroxetine - Drug Drug Interaction
Phase 1CompletedAsceneuron S.A.502024-02-222024-12-18
PET Study of Repeated ASN51 in Healthy Volunteers
ASN51 - Healthy
Phase 1CompletedAsceneuron S.A.122023-01-262025-05-08
Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51
ASN51 - Healthy Participants
Phase 1CompletedAsceneuron S.A.32021-08-092025-05-08
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
ASN51, Placebo - Alzheimer Disease
Phase 1TerminatedAsceneuron Pty Ltd.252021-06-022023-01-17

Conditions studied

Alzheimer Disease (2)

Interventions

Fluvoxamine (1)  ·  Itraconazole (1)  ·  Paroxetine (1)

Countries

United Kingdom (2)  ·  Australia (1)  ·  Netherlands (1)  ·  United States (1)

Top investigators

Adeep Puri, MD (1)  ·  Rolf Pokorny, MD (1)